Today, on the 11th of December 2025, the Board of Diagonal Bio AB (publ) has decided to submit a formal application for bankruptcy to the District Court of Lund. The application is planned to be submitted today.

The Board of Diagonal Bio announces the decision to submit a formal application for bankruptcy to the District Court of Lund. The decision is based on the fact that despite extensive work and efforts, the strained financial situation has not been solved. The application is planned to be submitted today.

For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com

Kerstin Jakobsson, Chairman
Phone: +46 70 550 45 40
E-mail: kj@diagonalbio.com

About Diagonal Bio
Diagonal Bio offers a point of care testing system for genetic markers that detects pathogens for viruses, bacteria and fungi. The system is approved for use in animals and current target markets are horses, small animals and fish farms. The Company has expertise in developing markers for eLAMP-testing that can be used on Diagonal’s own system or any other platform using LAMP technology, which creates a potential for licensing and partnerships in the future. Diagonal Bio was founded in 2020, is listed on NGM and headquartered in Lund, Sweden.

This information is information that Diagonal Bio is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-11 10:45 CET.

Attachments
Diagonal Bio intends to submit a formal application for bankruptcy